Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Launches $32.2M Stock Offering

NEW YORK (GenomeWeb) – NeoGenomics today said that it has priced an offering of 7 million shares of common stock at $4.60 per share.

The Ft. Myers, Fla.-based genetic testing services firm expects to raise gross proceeds of $32.2 million from the offering, which is expected to close on Aug. 20. Net proceeds are anticipated at around $30 million.

NeoGenomics said it will use the proceeds from the offering for working capital and general corporate purposes, which could include potential acquisitions and repayment of debt.

William Blair is the sole book-running manager on the offering, and Craig-Hallum Capital Group is co-lead manager. Stephens, Roth Capital Partners, Sidoti & Co., and Dawson James Securities are serving as co-managers on the offering.

The underwriters have a 30-day option to purchase up to an additional 1.05 million shares of common stock to cover any over-allotments.

NeoGenomics recently reported a 33 percent increase in second quarter revenues year over year and turned a profit in the quarter of $274,000, or $.01 per share. As of June 30 it held $5.0 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.